Impact of first line FOLFOXIRI and Bevacizumab (Bev) compared to FOLFOX and Bev on health related quality of life (HRQOL) in patients with metastatic colorectal cancer (MCRCR) - analysis of the CHARTA - AIO 0209 trial

ONCOLOGY RESEARCH AND TREATMENT(2017)

引用 0|浏览2
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要